Comparing Two Versions of Tenecteplase: Metalyse® vs. Mingfule®
Author Information
Author(s): Jan Bechmann, Ira Schmid, Simone Brand, Felix Miller, Chengzhi Zhang
Primary Institution: Boehringer Ingelheim Pharma GmbH and Co., KG
Hypothesis
This study aims to compare the fibrinolytic activity and overall product quality of the original tenecteplase, Metalyse®, to the copy, Mingfule®.
Conclusion
The study found significant differences in biochemical composition and clot lysis activity between Metalyse® and Mingfule®, raising questions about the generalizability of clinical data across different tenecteplase variants.
Supporting Evidence
- Mingfule® exhibited 13.5% lower clot lysis potency compared to Metalyse®.
- Mingfule® had a higher content of host cell proteins, indicating lower purity.
- Significant differences in glycosylation patterns were observed between the two products.
- Mingfule® showed dissimilar binding to clearance receptors compared to Metalyse®.
- Clinical implications of the differences in potency and purity need further investigation.
Takeaway
This study looked at two versions of a medicine called tenecteplase to see how well they work at breaking down blood clots. One version worked better than the other.
Methodology
The study used various quality testing assays, mass spectrometry analysis, and surface plasmon resonance assays to compare the two tenecteplase variants.
Potential Biases
Potential bias due to the involvement of authors from the original manufacturer of Metalyse®.
Limitations
The study was conducted in vitro, and the clinical implications of the findings need to be validated in clinical settings.
Statistical Information
P-Value
p<0.05
Confidence Interval
90%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website